A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
نویسندگان
چکیده
A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma Jonathon B. Cohen, Kami J. Maddocks, Ying Huang, Beth A. Christian, Samantha M. Jaglowski, Christopher R. Flowers & Kristie A. Blum To cite this article: Jonathon B. Cohen, Kami J. Maddocks, Ying Huang, Beth A. Christian, Samantha M. Jaglowski, Christopher R. Flowers & Kristie A. Blum (2017): A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma, Leukemia & Lymphoma, DOI: 10.1080/10428194.2017.1289527 To link to this article: http://dx.doi.org/10.1080/10428194.2017.1289527
منابع مشابه
Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملTreatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children
Hodgkin lymphoma (HL) accounts for about 10% of all childhood cancers. Five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. The current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. T...
متن کاملComplete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma.
644.8. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lympho-cyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by theGerman Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109-111.9. Advani RH, Horning SJ, Hoppe RT, et al. Frontline therapy of nodularlymphocyte predominant Hodgkin lymphoma with rituximab: the StanfordUniversi...
متن کاملClinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma
We retrospectively compared outcomes of patients with relapsed/refractory non-Hodgkin lymphoma (NHL) who underwent stem cell transplantation (SCT) with stable disease or better following a novel combination of lenalidomide and rituximab (LR) treatment and did not undergo SCT in a phase I/II clinical trial. We retrospectively compared outcomes of patients who underwent SCT with that of patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Leukemia & lymphoma
دوره 58 9 شماره
صفحات -
تاریخ انتشار 2017